

I.15 Self-management

Kernick D, Cox A, Powell R et al. A cost consequence study of the impact of a dermatology-trained practice nurse on the quality of life of primary care patients with eczema and psoriasis. Br J Gen Pract. 2000; 50:555-558. Ref ID: KERNICK2000				
Study details	Population & interventions	Costs	Health outcomes	Cost effectiveness
Economic analysis: CCA Study design: Within RCT analysis Approach to analysis:	Population: patients between 18 and 65 years who had a diagnosis of psoriasis (35%) or eczema (57%) or both (9%) Intervention 1:	Total costs (mean per patient): Intvn 1: NR Intvn 2: NR Currency & cost year: 1997 UK pounds	Primary outcome measure: QALYs (mean per patient) Intvn 1: 0.2127 Intvn 2: 0.2188 Incremental (2-1): 0.0062 (CI , ; p=NR)	Primary ICER (Intvn 2 vs Intvn 1): ICER: NR Subgroup analyses: NA Analysis of uncertainty: NR

Kernick D, Cox A, Powell R et al. A cost consequence study of the impact of a dermatology-trained practice nurse on the quality of life of primary care patients with eczema and psoriasis. Br J Gen Pract. 2000; 50:555-558. Ref ID: KERNICK2000

<p>DLQI and Euroqol QoL tool (0-100) were measured at baseline and 4 months later</p> <p>Perspective: UK NHS Time horizon: 4 months Treatment effect duration: NA Discounting: Costs = NA; Outcomes = NA</p>	<p>Routine GP care</p> <p>Baseline characteristics: Psoriasis: 35% Eczema: 57% Mixed: 9% Mean age = 47.4 (SD = ±18.4) Baseline DLQI: 6.1 (SD = ±4.9) Baseline Euroquol QoL: 62.9 (SD = ± 20.8)</p> <p>Intervention 2: Dermatology liaison nurse available in primary care</p> <p>Baseline characteristics: Psoriasis: 37% Eczema: 61% Mixed: 2% Mean age = 51.7 (SD = ±15.8) Baseline DLQI: 6.8 (SD = ±5.0) Baseline Euroquol QoL: 62.5 (SD = ± 23.1)</p>	<p>Cost components incorporated: Nurse and GP time for training and consultations</p>		
--	--	--	--	--

Data sources

Health outcomes: Health outcomes in terms of change in DLQI and change in Euroqol QoL as measured on a visual analogue scale were evaluated directly in the trial. Other qualitative outcomes were also reported and included in the clinical evidence review.

Quality-of-life weights: Euroqol QoL was measured on a visual analogue scale directly from patients.

Cost sources: Costs for nursing and GP time were taken from *Unit costs of health and social care* (Netten 1997).

Comments

Source of funding: Leo Pharmaceuticals

Kernick D, Cox A, Powell R et al. A cost consequence study of the impact of a dermatology-trained practice nurse on the quality of life of primary care patients with eczema and psoriasis. Br J Gen Pract. 2000; 50:555-558. Ref ID: KERNICK2000

Limitations: The population is a mixture of patients with psoriasis and eczema; costs are not aggregated and presented as mean/median cost per patient; costs of topicals and any other treatments administered not included; unit costs are out of date for current decision-making; no incremental analysis could be performed for costs; no sensitivity analyses were undertaken; funded by Leo Pharmaceuticals, makers of vitamin D analogues and combined vitamin D analogue and potent corticosteroid products.

Other:

Overall applicability*: Partially applicable **Overall quality**:** Very serious limitations